Genelux (GNLX) Cash from Investing Activities (2022 - 2026)
Genelux (GNLX) posted quarterly Cash from Investing Activities of -$8.5 million for Q1 2026, down 343.35% year-over-year from $3.5 million in Q1 2025, and down 230.09% quarter-over-quarter from $6.6 million in Q4 2025.
Genelux (GNLX) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Genelux's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$8.5 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 343.35% year-over-year to -$8.5 million; the TTM figure through Mar 2026 stood at $93000.0 (up 103.17% YoY), while the FY2025 annual figure was $12.1 million, up 249.32% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$8.5 million, down from $6.6 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $6.7 million in Q4 2024, with the low at -$17.1 million in Q2 2024.
- The 5-year median for Cash from Investing Activities is -$193000.0 (2023), against an average of -$1.4 million.
- Peak annual rise in Cash from Investing Activities reached 1541.16% in 2024, while the deepest fall reached 4219.7% in 2024.
- Genelux's Cash from Investing Activities stood at -$15000.0 in 2022, then sank by 92846.67% to -$13.9 million in 2023, then jumped by 147.87% to $6.7 million in 2024, then decreased by 1.65% to $6.6 million in 2025, then plunged by 230.09% to -$8.5 million in 2026.
- Business Quant data shows GNLX's Cash from Investing Activities at -$8.5 million in Q1 2026, $6.6 million in Q4 2025, and $4.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | -8.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.54 Mn |
| Mar 31, 2026 | -8.54 Mn |
| Dec 31, 2025 | 6.56 Mn |
| Dec 31, 2025 | 6.56 Mn |
| Sep 30, 2025 | 4.72 Mn |
| Sep 30, 2025 | 4.72 Mn |
| Jun 30, 2025 | -2.65 Mn |
| Jun 30, 2025 | -2.65 Mn |
| Mar 31, 2025 | 3.51 Mn |
| Mar 31, 2025 | 3.51 Mn |
| Dec 31, 2024 | 6.67 Mn |
| Dec 31, 2024 | 6.67 Mn |
| Sep 30, 2024 | 3.99 Mn |
| Sep 30, 2024 | 3.99 Mn |
| Jun 30, 2024 | -17.11 Mn |
| Jun 30, 2024 | -17.11 Mn |
| Mar 31, 2024 | -1.69 Mn |
| Mar 31, 2024 | -1.69 Mn |
| Dec 31, 2023 | -13.94 Mn |
| Dec 31, 2023 | -13.94 Mn |